New Zealand markets closed

InspireMD, Inc. (NSPR)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.4806-0.0294 (-1.95%)
At close: 04:00PM EDT
1.4600 -0.02 (-1.39%)
After hours: 05:48PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.5100
Open1.5300
Bid1.4600 x 1400
Ask1.5300 x 800
Day's range1.4300 - 1.5300
52-week range1.4300 - 4.6500
Volume10,025
Avg. volume14,560
Market cap12.323M
Beta (5Y monthly)1.22
PE ratio (TTM)N/A
EPS (TTM)-2.0800
Earnings date07 Nov 2022 - 11 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.60
  • GlobeNewswire

    InspireMD Announces Presentation at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) Conference

    TEL AVIV, Israel, Sept. 13, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced that the company will deliver a presentation at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) Conference, which is being held September 16-19, 2022, at the Boston Convention and Exhibition Center in Boston, MA. Details of the presentation are as follows: Title:Endovascular Sequestration of High-Risk

  • Business Wire

    NAMSA and InspireMD Announce Strategic Outsourcing Partnership to Accelerate New Product Development

    TOLEDO, Ohio & TEL AVIV, Israel, September 08, 2022--NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, and InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for treatment of carotid artery disease and prevention of stroke, announced today that they have entered into a strategic outsourcing partnership to accelerate medical device development and commercialization.

  • GlobeNewswire

    InspireMD Reports Second Quarter 2022 Financial Results and Provides Business Update

    - Generated 47.8% growth in CGuard™ revenue year-over-year - - Delivered several presentations at LINC 2022 featuring CGuard™ EPS, including a successful live case transmission - - Announced that endovascular pioneer Dr. Juan Parodi has agreed to act as strategic advisor to the company - --Management to Host Investor Conference Call Today, August 9th, at 8:30am ET-- TEL AVIV, Israel, Aug. 09, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Sys